Histology and its prognostic effect on KRAS‑mutated colorectal carcinomas in Korea
- Authors:
- Hye Seung Lee
- Dae Yong Hwang
- Hye Seung Han
-
Affiliations: Department of Pathology, Korea Clinical Laboratory, Seoul 05396, Republic of Korea, Department of Surgery, Konkuk University School of Medicine, Seoul 05030, Republic of Korea, Department of Pathology, Konkuk University School of Medicine, Seoul 05030, Republic of Korea - Published online on: May 13, 2020 https://doi.org/10.3892/ol.2020.11606
- Pages: 655-666
-
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Shin A, Kim KZ, Jung KW, Park S, Won YJ, Kim J, Kim DY and Oh JH: Increasing trend of colorectal cancer incidence in Korea, 1999–2009. Cancer Res Treat. 44:219–226. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jung KW, Won YJ, Kong HJ and Lee ES: Prediction of cancer incidence and mortality in Korea, 2018. Cancer Res Treat. 50:317–323. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al: Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5-a population-based study. Lancet Oncol. 15:23–34. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mundade R, Imperiale TF, Prabhu L, Loehrer PJ and Lu T: Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience. 1:400–406. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Castagnola P and Giaretti W: Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta. 1756:115–125. 2005.PubMed/NCBI | |
|
Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, et al: Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res. 14:2560–2569. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Malumbres M and Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, et al: Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol. 26:825–834. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka M, Omura K, Watanabe Y, Oda Y and Nakanishi I: Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol. 57:57–64. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Kakar S, Aksoy S, Burgart LJ and Smyrk TC: Mucinous carcinoma of the colon: Correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol. 17:696–700. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rimbert J, Tachon G, Junca A, Villalva C, Karayan-Tapon L and Tougeron D: Association between clinicopathological characteristics and RAS mutation in colorectal cancer. Mod Pathol. 31:517–526. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Millar J: The Need for a Global Language-SNOMED CT introduction. Stud Health Technol Inform. 225:683–685. 2016.PubMed/NCBI | |
|
Yang D, Lai X, Xu F, Li Y, Jiang W and Ma D: Prognosis and clinical characteristics of colorectal cancer patients with KRAS gene mutation: A 5-year follow-up study. Int J Clin Exp Pathol. 12:409–418. 2019.PubMed/NCBI | |
|
Lim DR, Kuk JK, Kim T and Shin EJ: Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? Medicine (Baltimore). 96:e82412017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CH, Hsieh MC, Hsiao PK, Lin EK, Lu YJ and Wu SY: A critical reappraisal for the value of tumor size as a prognostic variable in rectal adenocarcinoma. J Cancer. 8:1927–1934. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai ZW and Gu J: Influence of tumor size on the prognosis in patients with colon cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 15:495–498. 2012.(In Chinese). PubMed/NCBI | |
|
Oh SY, Han JY, Lee SR and Lee HT: Improved DNA extraction method for molecular diagnosis from smaller numbers of cells. Korean J Clin Lab Sci. 46:99–105. 2014. View Article : Google Scholar | |
|
Bosman FT, Carneiro F, Hruban RH and Theise ND: WHO classification of tumours of the digestive system. Fourth Edition. IARC. 2010. | |
|
Weiser MR: AJCC 8th edition: Colorectal cancer. Ann Surg Oncol. 25:1454–1455. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Onodera M, Nishigami T, Torii I, Sato A, Tao LH, Kataoka TR, Yoshikawa R and Tsujimura T: Comparison between colorectal low- and high-grade mucinous adenocarcinoma with MUC1 and MUC5AC. World J Gastrointest Oncol. 1:69–73. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ueno H, Hashiguchi Y, Shimazaki H, Shinto E, Kajiwara Y, Nakanishi K, Kato K, Maekawa K, Miyai K, Nakamura T, et al: Objective criteria for crohn-like lymphoid reaction in colorectal cancer. Am J Clin Pathol. 139:434–441. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shia J, Schultz N, Kuk D, Vakiani E, Middha S, Segal NH, Hechtman JF, Berger MF, Stadler ZK, Weiser MR, et al: Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: Clinical and biological implications. Mod Pathol. 30:599–609. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Iseki Y, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K and Ohira M: A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS One. 13:e01927442018. View Article : Google Scholar : PubMed/NCBI | |
|
Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, El Zimaity H, Flèjou JF, Hansen TP, Hartmann A, et al: Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 30:1299–1311. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kruschewski M, Mueller K, Lipka S, Budczies J, Noske A, Buhr HJ and Elezkurtaj S: The prognostic impact of p53 expression on sporadic colorectal cancer is dependent on p21 status. Cancers (Basel). 3:1274–1284. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M and Fuchs CS: Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol. 210:147–154. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Guo F, Gong H, Zhao H, Chen J, Zhang Y, Zhang L, Shi X, Zhang A, Jin H, Zhang J and He Y: Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep. 8:60762018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee WS, Lee JN, Baek JH and Park YH: RAS status in Korean patients with stage III and IV colorectal cancer. Clin Transl Oncol. 17:751–756. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, et al: The impact of primary tumor location in patients with metastatic colorectal cancer: A Korean Cancer Study Group CO12-04 study. Korean J Intern Med. 34:165–177. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, Castagnola P and Giaretti W: KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Cell Oncol. 28:161–166. 2006.PubMed/NCBI | |
|
Tosi F, Magni E, Amatu A, Mauri G, Bencardino K, Truini M, Veronese S, De Carlis L, Ferrari G, Nichelatti M, et al: Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: A systematic review and meta-analysis. Clin Colorectal Cancer. 16:e153–e163. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bai B, Shan L, Xie B, Huang X, Mao W, Wang X, Wang D and Zhu H: Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer. Oncol Lett. 15:3161–3166. 2018.PubMed/NCBI | |
|
Lee JH, Ahn J, Park WS, Choe EK, Kim E, Shin R, Heo SC, Jung S, Kim K, Chai YJ and Chae H: Colorectal cancer prognosis is not associated with BRAF and KRAS Mutations-A STROBE compliant study. J Clin Med. 8(pii): E1112019. View Article : Google Scholar : PubMed/NCBI | |
|
Payandeh M, Shazad B, Sadeghi M and Shahbazi M: Correlation between RAS test results and prognosis of metastatic colorectal cancer patients: A report from Western Iran. Asian Pac J Cancer Prev. 17:1729–1732. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, Laubender RP, Ocvirk J, Kurteva G, Papai Z, Knittelfelder R, et al: Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: A pooled analysis of three trials. Oncology. 83:241–247. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Renaud S, Guerrera F, Seitlinger J, Costardi L, Schaeffer M, Romain B, Mossetti C, Claire-Voegeli A, Filosso PL, Legrain M, et al: KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer. Oncotarget. 8:2514–2524. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D and Malik HZ: Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 116:923–929. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, et al: FOLFOX4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor RAS and BRAF mutation status: Updated analysis of the CECOG/CORE 1.2.002 study. Clin Colorectal Cancer. 14:91–98. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, et al: KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 20:3033–3043. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, et al: Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol. 21:1275–1283. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA. 307:1383–1393. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, et al: KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol. 22:187–194. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Blons H, Emile JF, Le Malicot K, Juliè C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, et al: Prognostic value of KRAS mutations in stage III colon cancer: Post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol. 25:2378–2385. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Won DD, Lee JI, Lee IK, Oh ST, Jung ES and Lee SH: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. BMC Cancer. 17:4032017. View Article : Google Scholar : PubMed/NCBI | |
|
Gao XH, Yu GY, Hong YG, Lian W, Chouhan H, Xu Y, Liu LJ, Bai CG and Zhang W: Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients. Int J Clin Oncol. 24:141–152. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Natsume S, Yamaguchi T, Takao M, Iijima T, Wakaume R, Takahashi K, Matsumoto H, Nakano D, Horiguchi SI, Koizumi K and Miyaki M: Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. Jpn J Clin Oncol. 48:609–618. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue Y, Saigusa S, Iwata T, Okugawa Y, Toiyama Y, Tanaka K, Uchida K, Mohri Y and Kusunoki M: The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Rep. 28:1579–1584. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chang MH, Lee IK, Si Y, Lee KS, Woo IS and Byun JH: Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Chemother Pharmacol. 68:317–323. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HS, Heo JS, Lee J, Lee JY, Lee MY, Lim SH, Lee WY, Kim SH, Park YA, Cho YB, et al: The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: A retrospective analysis. BMC Cancer. 16:1202016. View Article : Google Scholar : PubMed/NCBI | |
|
Buim ME, Fanelli MF, Souza VS, Romero J, Abdallah EA, Mello CA, Alves V, Ocea LM, Mingues NB, Barbosa PN, et al: Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol Ther. 16:1289–1295. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cabrera-Mendoza F, Gainza-Lagunes S, Castañeda-Andrade I and Castro-Zarate A: Clinical relevance of the K-ras oncogene in colorectal cancer: Experience in a Mexican population. Rev Gastroenterol Mex. 79:166–170. 2014.(In Spanish). PubMed/NCBI | |
|
Zekri J, Rizvi A, Al-Maghrabi J and Bin Sadiq B: K-ras in colorectal cancer tumors from saudi patients: Frequency, Clinco-pathological Association and clinical outcome. Open Colorectal Cancer J. 5:22–27. 2012. View Article : Google Scholar | |
|
Sastre J, Vidaurreta M, Gómez A, Rivera F, Massutí B, López MR, Abad A, Gallen M, Benavides M, Aranda E, et al: Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer. 12:280–286. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Serenari M, Alvarez FA, Ardiles V, de Santibañes M, Pekolj J and de Santibañes E: The ALPPS approach for colorectal liver metastases: Impact of KRAS mutation status in survival. Dig Surg. 35:303–310. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Graf W, Cashin PH, Ghanipour L, Enblad M, Botling J, Terman A and Birgisson H: Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 27:293–300. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Winder T, Mündlein A, Rhomberg S, Dirschmid K, Hartmann BL, Knauer M, Drexel H, Wenzl E, De Vries A and Lang A: Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep. 21:1283–1287. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, Leedham SJ, Phull PS, Rutter MD, Shepherd NA, et al: British society of gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 66:1181–1196. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee CT, Huang YC, Hung LY, Chow NH, Su PF, Ho CL, Tsai HW, Chen YL, Lin SC, Lin BW, et al: Serrated adenocarcinoma morphology in colorectal mucinous adenocarcinoma is associated with improved patient survival. Oncotarget. 8:35165–35175. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Patai AV, Molnár B, Tulassay Z and Sipos F: Serrated pathway: Alternative route to colorectal cancer. World J Gastroenterol. 19:607–615. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Loy TS and Kaplan PA: Villous adenocarcinoma of the colon and rectum: A clinicopathologic study of 36 cases. Am J Surg Pathol. 28:1460–1465. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Palazzo JP, Edmonston TB, Chaille-Arnold LM and Burkholder S: Invasive papillary adenocarcinoma of the colon. Hum Pathol. 33:372–375. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gonzalez RS, Cates JM, Washington MK, Beauchamp RD, Coffey RJ and Shi C: Adenoma-like adenocarcinoma: A subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. Histopathology. 68:183–190. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fecteau RE, Lutterbaugh J, Markowitz SD, Willis J and Guda K: GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. PLoS One. 9:e879662014. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MJ, Hong SM, Jang SJ, Yu E, Kim JS, Kim KR, Gong G and Ro JY: Invasive colorectal micropapillary carcinoma: An aggressive variant of adenocarcinoma. Hum Pathol. 37:809–815. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Pettinato G, Manivel CJ, Panico L, Sparano L and Petrella G: Invasive micropapillary carcinoma of the breast: Clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol. 121:857–866. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W and Lenz HJ: Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res. 15:6391–6397. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Majek O, Gondos A, Jansen L, Emrich K, Holleczek B, Katalinic A, Nennecke A, Eberle A and Brenner H; GEKID Cancer Survival Working Group, : Sex differences in colorectal cancer survival: Population-based analysis of 164,996 colorectal cancer patients in Germany. PLoS One. 8:e680772013. View Article : Google Scholar : PubMed/NCBI | |
|
Soulierès D, Greer W, Magliocco AM, Huntsman D, Young S, Tsao MS and Kamel-Reid S: KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol. 17 (Suppl 1):S31–S40. 2010.PubMed/NCBI | |
|
Chuko J, Yeh MK, Chen BJ and Hu KY: Efficacy of cetuximab on wild-type and mutant KRAS in colorectal cancer: Systematic review and meta-analysis. J Med Sci. 30:189–198. 2010. | |
|
Pollheimer MJ, Kornprat P, Lindtner RA, Harbaum L, Schlemmer A, Rehak P and Langner C: Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol. 41:1749–1757. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Väyrynen SA, Väyrynen JP, Klintrup K, Mäkelä J, Karttunen TJ, Tuomisto A and Mäkinen MJ: Clinical impact and network of determinants of tumour necrosis in colorectal cancer. Br J Cancer. 114:1334–1342. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wikberg ML, Ling A, Li X, Öberg A, Edin S and Palmqvist R: Neutrophil infiltration is a favorable prognostic factor in early stages of colon cancer. Hum Pathol. 68:193–202. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rao HL, Chen JW, Li M, Xiao YB, Fu J, Zeng YX, Cai MY and Xie D: Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PLoS One. 7:e308062012. View Article : Google Scholar : PubMed/NCBI | |
|
Sanz-Garcia E, Argiles G, Elez E and Tabernero J: BRAF mutant colorectal cancer: Prognosis, treatment, and new perspectives. Ann Oncol. 28:2648–2657. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, Wang YX, Shi DC, Huang Q and Fu WL: BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: A systematic review and meta-analysis. PLoS One. 9:e906072014. View Article : Google Scholar : PubMed/NCBI | |
|
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI |
